Clinical studies of bay o 9867 (ciprofloxacin)in skin infections

Masutaka Furue; Sook Hyang Yoon; Hong Il Yoon; Naoshige Horie; Yasuo Kubota; Kimiko Ogawa; Shotaro Harada

doi:10.11250/chemotherapy1953.33.Supplement7_946

Clinical studies of bay o 9867 (ciprofloxacin)in skin infections

Masutaka Furue, Sook Hyang Yoon, Hong Il Yoon, Naoshige Horie, Yasuo Kubota, Kimiko Ogawa, Shotaro Harada

Research output: Contribution to journal › Article › peer-review

Abstract

The clinical efficacy of BAY o 9867, a new quinoline carboxylic acid derivative, was studied in dermatological infectious diseases. BAY o 9867 was administered to 33 patients with various skin infectious diseases. The dose was 300~600mg and the duration of administration was 3 to 17 days. The isolated organisms from affected sites were S. aureus, S. epidermidis, P. acnes, S. capitis, Peptostreptococcus, P. avidum, S. pyogenes, S. xylosus. S. aureus and S. epidermidis were all eliminated. Clinical results were excellent in 8 cases, good in 21cases, fair in 2 cases and poor in 2 cases. The overall efficacy rate was 87.9%. As the side effect of BAY o 9867, mild heartburn was noted in 1 case. As the abnormal changes in laboratory data, slight increase of BUN was found in only 1 case.

Original language	English
Pages (from-to)	946-950
Number of pages	5
Journal	Chemotherapy
Volume	33
DOIs	https://doi.org/10.11250/chemotherapy1953.33.Supplement7_946
Publication status	Published - Jan 1 1985
Externally published	Yes

All Science Journal Classification (ASJC) codes

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.33.Supplement7_946

Cite this

@article{95bc12e0ac4a40699dd239bdba4a85a6,

title = "Clinical studies of bay o 9867 (ciprofloxacin)in skin infections",

abstract = "The clinical efficacy of BAY o 9867, a new quinoline carboxylic acid derivative, was studied in dermatological infectious diseases. BAY o 9867 was administered to 33 patients with various skin infectious diseases. The dose was 300~600mg and the duration of administration was 3 to 17 days. The isolated organisms from affected sites were S. aureus, S. epidermidis, P. acnes, S. capitis, Peptostreptococcus, P. avidum, S. pyogenes, S. xylosus. S. aureus and S. epidermidis were all eliminated. Clinical results were excellent in 8 cases, good in 21cases, fair in 2 cases and poor in 2 cases. The overall efficacy rate was 87.9%. As the side effect of BAY o 9867, mild heartburn was noted in 1 case. As the abnormal changes in laboratory data, slight increase of BUN was found in only 1 case.",

author = "Masutaka Furue and Yoon, {Sook Hyang} and Yoon, {Hong Il} and Naoshige Horie and Yasuo Kubota and Kimiko Ogawa and Shotaro Harada",

year = "1985",

month = jan,

day = "1",

doi = "10.11250/chemotherapy1953.33.Supplement7_946",

language = "English",

volume = "33",

pages = "946--950",

journal = "Chemotherapy",

issn = "0009-3165",

}

TY - JOUR

T1 - Clinical studies of bay o 9867 (ciprofloxacin)in skin infections

AU - Furue, Masutaka

AU - Yoon, Sook Hyang

AU - Yoon, Hong Il

AU - Horie, Naoshige

AU - Kubota, Yasuo

AU - Ogawa, Kimiko

AU - Harada, Shotaro

PY - 1985/1/1

Y1 - 1985/1/1

N2 - The clinical efficacy of BAY o 9867, a new quinoline carboxylic acid derivative, was studied in dermatological infectious diseases. BAY o 9867 was administered to 33 patients with various skin infectious diseases. The dose was 300~600mg and the duration of administration was 3 to 17 days. The isolated organisms from affected sites were S. aureus, S. epidermidis, P. acnes, S. capitis, Peptostreptococcus, P. avidum, S. pyogenes, S. xylosus. S. aureus and S. epidermidis were all eliminated. Clinical results were excellent in 8 cases, good in 21cases, fair in 2 cases and poor in 2 cases. The overall efficacy rate was 87.9%. As the side effect of BAY o 9867, mild heartburn was noted in 1 case. As the abnormal changes in laboratory data, slight increase of BUN was found in only 1 case.

AB - The clinical efficacy of BAY o 9867, a new quinoline carboxylic acid derivative, was studied in dermatological infectious diseases. BAY o 9867 was administered to 33 patients with various skin infectious diseases. The dose was 300~600mg and the duration of administration was 3 to 17 days. The isolated organisms from affected sites were S. aureus, S. epidermidis, P. acnes, S. capitis, Peptostreptococcus, P. avidum, S. pyogenes, S. xylosus. S. aureus and S. epidermidis were all eliminated. Clinical results were excellent in 8 cases, good in 21cases, fair in 2 cases and poor in 2 cases. The overall efficacy rate was 87.9%. As the side effect of BAY o 9867, mild heartburn was noted in 1 case. As the abnormal changes in laboratory data, slight increase of BUN was found in only 1 case.

UR - http://www.scopus.com/inward/record.url?scp=0022366202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022366202&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.33.Supplement7_946

DO - 10.11250/chemotherapy1953.33.Supplement7_946

M3 - Article

AN - SCOPUS:0022366202

SN - 0009-3165

VL - 33

SP - 946

EP - 950

JO - Chemotherapy

JF - Chemotherapy

ER -

Clinical studies of bay o 9867 (ciprofloxacin)in skin infections

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this